Prescription pharmaceuticals are drugs that cannot be sold over-the-counter without a written directive from a licensed physician. The global pharmaceutical market was worth approximately $650 billion (at the manufacturer’s level). The market has continued its recovery from the economic downfall experienced in recent years. Sales for pharmaceuticals increased slightly The largest therapeutic areas in medicine are: cardiovascular disease and blood disorders, neuroscience, infection, cancer, respiratory and inflammation and others. The following reports provide market information for prescription pharmaceuticals.
- Sort by Product ID
- Display 45 Products per page
Published: January 1, 2003 | Price: $2,500.00 – $5,000.00
Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the $20 billion world market in infectious disease drugs. However, it’s also the most crowded of the segments with big pharma and small biotech companies alike...Published: March 1, 2003 | Price: $2,812.00 – $5,625.00
During the last 25 years, there have been unprecedented advancements in the area of women’s health and there is widespread recognition of the importance of addressing conditions that overwhelmingly affect women. Likewise, pharmaceutical marketers have increasingly understood the potential that the women’s health market represents and the increasing clout female consumers are wielding in the prescription drug marketplace. Women’s Health: Worldwide Prescription Drug Markets is a comprehensive study of the pharmaceutical markets aimed at diseases and conditions that affect women....Published: April 1, 2003 | Price: $1,875.00 – $3,750.00
This report analyzes the world markets for human antiviral medications, focusing on the current market for and the development of drugs that are used to directly combat and treat viruses viral infections. For the purposes of this report, antivirals are drugs used to directly treat viral infection after it occurs. The report does not discuss products for the prevention of viral infection—that is, adult or pediatric vaccinations—and does not discuss other diseases, such as cancer or heart disease, that may...Published: April 1, 2003 | Price: $6,000.00 – $12,000.00
Once a public health problem pegged for easy elimination, infectious diseases continue to be the leading cause of death worldwide. Despite improved methods of treating and preventing infection, including potent antibiotics, comprehensive immunization, and modern sanitation, infection still accounts for much serious illness, even in highly industrialized countries. Use this new Kalorama Information 3-volume series to evaluate your organization's position in the highly active anti-infectives market. Volume I Abstract The World Market for Antifungal Medications The market for pharmaceuticals targeted...Published: May 1, 2003 | Price: $2,625.00 – $5,250.00
Switching dosages and ingredients of prescription medicines to the over-the-counter market is not new. In the past 30 years, more than 70 switches have produced hundreds of brands competing in the consumer market, and the pace promises to accelerate. Going OTC is one of a number of strategies marketers can use to extend the revenue life of their products. Appropriately coordinating the switch with patent expiry, creating coherent branding strategies, and knowing the clinical consumer climate are all factors in...Published: November 1, 2003 | Price: $2,246.00 – $4,492.00
Rheumatoid arthritis is a progressive disease of the joint structure that may be localized or systemic. It varies significantly in severity, producing symptoms that range from minor aches to severe disability and joint deformity. While rheumatoid arthritis can be diagnosed at any age, for childhood to the later years, it most commonly presents with significant symptoms at about middle age. From that point, the disease can progress quickly, slowly or virtually not at all. With an aging population, the unmet...Published: January 1, 2004 | Price: $2,995.00 – $5,990.00
Type II diabetes is a metabolic disease the increases in incidence and prevalence with age. Type II diabetes (also known as "adult onset diabetes" and "non-insulin dependent diabetes") is a disease of glucose metabolism in which the individual becomes resistant to the glucose produced by the pancreas. As a result, glucose is not properly metabolized and serum glucose levels are increased, resulting in numerous complications vascular, renal, neurological and ophthalmological complications as the patient ages. This volume of the Markets...Published: February 1, 2004 | Price: $3,500.00 – $7,000.00
This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fourth time Kalorama Information has comprehensively studied the dermatology markets. For this latest edition, Kalorama completely re-evaluated the market from the ground up, and in addition to the usual primary interviewing of industry participants, clinicians, and regulators, we also conducted scores of interviews with users of...Published: March 1, 2004 | Price: $2,995.00 – $5,990.00
Cardiovascular disease includes chronic conditions such as hypertension, congestive heart failure and atherosclerosis, as well as such acute conditions as myocardial infarction and cardiac arrest. While cardiovascular disease may be diagnosed at any age, it is most prevalent in later years, particularly among sedentary individuals who are also overweight or obese. With the aging of the "Baby Boom" generation, a generation that has defined the term "couch potato" and has grown up on and maintained a diet of fast-food, the...Published: March 1, 2004 | Price: $795.00 – $1,590.00
The hard-fought battle over Medicare's prescription drug benefit is over, but the long-term effects of the new law are still unclear. Exactly who will benefit and by how much? Is it a victory for big pharma? Initial reactions are not always correct, and this examination into the true implications for pharmaceutical markets looks at all the facts. This market briefing from Kalorama describes and assesses the provisions of the "Medicare Prescription Drug, Improvement and Modernization Act of 2003" and predicts...Published: April 1, 2005 | Price: $995.00 – $1,990.00
Schizophrenia is a life long affliction. There is no permanent cure for this illness. However, numerous drugs have made the effective management of the disease a reality. This briefing examines both corrent and emerging therapeutic approaches for the management of schizophrenia. It provides an analysis of the current and future markets for these agents, including forecasts to 2009 segmented by geographic region and by type of drug and likely market scenarios for new agents not yet available. The briefing discusses...Published: April 1, 2005 | Price: $2,500.00 – $5,000.00
In the past 100 years, there has been a steady increase in the incidence of serious secondary systemic fungal infections. One of the factors aiding the spread of fungal disease has been the widespread use of broad-spectrum antibiotics, which eliminate or decrease the non-pathogenic bacterial populations that normally compete with fungi. Another has been the vast increase in populations with with compromised immune response (caused by AIDS or by the action of immunosuppressant drugs or cancer chemotherapy agents). In addition...Published: May 1, 2005 | Price: $3,500.00 – $7,000.00
The worldwide market for prescription cardiovascular drugs encompasses a wide variety of products that treat the many facets of cardiovascular disease. The field of cardiology is currently experiencing a busy and dynamic period. As a result, the range of therapeutic options available to physicians has expanded significantly in the past few years and the development pipeline promises even more weapons soon. The sheer size and diversity of the current market and the potential of new products make this therapeutic category...Published: May 1, 2005 | Price: $2,500.00 – $5,000.00
For the past 60 years, antibiotic drugs have changed bacterial infections from the life-threatening scourges they once were into eminently treatable conditions. However, the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to traditional agents. As a result, pharmaceutical companies are taking a second look at the antibiotic market, after more than two decades of relative complacency. In addition to the scientific and technical challenges of new antibiotic development, there are significant...Published: June 1, 2005 | Price: $2,500.00 – $5,000.00
This volume of Kalorama Information’s World Market for Anti-Infectives series focuses on three general product segments of antiviral treatment: Nucleoside Analogs Protease Inhibitors Other Misc. Antivirals The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides an An overview Description of products on the market Description of products in development Market estimates and forecasts through 2009 Market segmentation by infection type Market segmentation by geographic region Market share of leading...Published: September 1, 2005 | Price: $3,500.00 – $7,000.00
Management of both acute and chronic neurologic diseases can be challenging for both the patient and the health care provider. Many neurologic disorders involve progressive deterioration in physical and mental capabilities, which can be devastating to the patient and the patient’s family. In many respects, neurotherapeutics represent the largest as-yet untapped market in medicine. This Kalorama Information report focuses on several key product segments of neurotherapeutic treatment: Alzheimer’s Disease and Other Dementias Brain and Neurologic Cancers Brain Trauma and Stroke...Published: November 1, 2005 | Price: $3,500.00 – $7,000.00
Although, the next 15-20 years will shift a majority of the population into the elderly population group, children will continue to remain the bulk of the dependent population worldwide with 9 in every 10 people falling into a pediatric age range in the less developed regions of Africa, Asia and Latin America. Therefore, the treatment of conditions and diseases affecting pediatrics and the healthy growth of children are vital to providing a solid foundation for healthy adults in the future....Published: February 1, 2006 | Price: $1,995.00 – $7,800.00
This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fifth time Kalorama Information has comprehensively studied the dermatology markets. As is the case with each new edition, Kalorama completely re-evaluated the market from the ground up, and in addition to the usual primary interviewing of industry participants, clinicians, and regulators, we also conducted scores of...Published: April 1, 2006 | Price: $2,500.00 – $7,000.00
The landscape of generic companies is changing: their relative might in the industry is increasing and the product lines their offering are growing in depth and breadth. Strong growth in the sector has come not only from more aggressive tactics and better acceptance in the clinical and consumer population, but by the loss of patent protection in the past few years of some huge-name drugs, including Prozac, Zocor, Prilosec, Prevacid, Sporanox, Evista, Flovent, Claritin, Allegra, Diflucan, Zofran, Zoloft, and Pravachol....Published: June 1, 2006 | Price: $995.00 – $5,990.00
This report focuses on the specific needs and market applications of the critical care pharmaceuticals market, the options presented by the market, the factors associated with strategic market development, and prospects for the future. The major indications for critical care are discussed as well as the range of pharmaceutical products used in the critical care environment. The strategic market characteristics of the critical care pharmaceuticals market are also discussed. The trends —- cost-containment programs, restricted formulary acceptance, clinical pharmacy, and...Published: July 1, 2006 | Price: $2,995.00 – $7,800.00
Ophthalmology is entering one of the most remarkable phases in recent history of this industry; new technologies and treatment modalities for both visual acuity and major eye diseases may dramatically change the composition and competitive dynamics of this market. As RK and LASIK changed the market a few years ago, even newer competitive technologies are just now emerging. From the advent of photodynamic therapy and new drug delivery techniques to revolutionary surgical approaches to refractive vision correction, ophthalmology is poised...Published: July 1, 2006 | Price: $995.00 – $7,000.00
This report provides and in-depth analysis of the market for prescription drugs used in the treatment of gastrointestinal (GI) disorders, such as nausea and vomiting, heartburn, gastro-esophageal reflux disease (GERD), ulcer, cancers of the GI tract (colorectal, esophageal, and gastric), Crohn’s disease, ulcerative colitis, irritable bowel syndrome (IBS), diverticular disease, constipation, celiac disease, short bowel syndrome, diarrhea, intestinal obstruction, and digestive enzyme disorders. For each major segment, the analysis provides an overview of the diseases including epidemiology, a detailed description...Published: September 1, 2006 | Price: $3,900.00 – $7,800.00
This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. The report contains vital market statistics on three main segments of pharmaceutical contract manufacturing: Biopharmaceutical manufacturing, including monoclonal antibodies (MAbs), complex proteins, peptides, nucleotides, DNA vaccines, and gene therapy. Primary pharmaceutical manufacturing, including non-sterile and sterile active pharmaceutical ingredients (APIs), custom chemicals, certain specialized manufacturing...Published: October 1, 2006 | Price: $995.00 – $7,000.00
The orthopedic drug market is a highly competitive market and, in some areas, the competitive environment is being shaped by increasing levels of generic competition. Several large pharmaceutical companies compete in the orthopedic drug market, including Abbott, Eli Lilly, GlaxoSmithKline, Merck, Novartis, and Pfizer among others, and several other suppliers, such as Serono, NovoNordisk, Amgen, and Genentech are developing or offering products in more niche market areas. For the purposes of this study, the world market for orthopedic drugs has...Published: January 1, 2007 | Price: $995.00 – $7,000.00
The market for psychotherapeutics drugs is about to change dramatically -- and serious pharmaceutical market watchers will want to be prepared. Kalorama’s Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs: World Market is the most exhaustive guide available to this booming market and the direction it is headed in the next four years. Psychotherapeutics treat conditions classified as abnormal behavior, thoughts and feelings that persist for a determined amount of time causing distress or emotional/physical impairment. Depression, anxiety, psychosis, ADHD and nicotine and...Published: March 1, 2007 | Price: $2,500.00 – $5,990.00
Over one billion people suffer from fungal infections worldwide, and this number is growing Though Athlete's foot, dandruff, vaginal yeast infection and fungal nail make up the bulk of these cases, there has been a steady increase in the incidence of more serious infections. This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. The increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy has also been...Published: April 1, 2007 | Price: $2,995.00 – $5,990.00
The market for antibiotics has changed and a knowledge of the current drug resistance situation is critical before operating in this marketplace. The effectiveness of many antibacterials (antibiotics) is being reduced as more and more types of bacteria become resistant to them. These and other developments are covered in Kalorama's Anti-Infectives, World Markets, Vol. II: Antibacterials providing extensive detail on the anti-bacterial market, including the following critical trends: Drug resistance and Interactions Antibiotic Abuse Antibiotic Cycling Addressing Market Trends Antibiotic...Published: April 1, 2007 | Price: $1,295.00 – $2,995.00
SMOKING CESSATION IS AN increasingly important area of focus for pharmaceutical companies, healthcare entities and governments. There are 1.4 billion smokers in the world, and smoking is a known cause of heart disease, lung cancer, respiratory infections and many other diseases. This has created a large market for smoking cessation aids. The market, which Zyban currently holds a tenuous lock on, is about to change, with a major new brand ready to shake up the current market share. At the...Published: July 1, 2007 | Price: $5,995.00 – $11,990.00
This series provides total coverage of the Anti-Infectives market, a market that is changing due to product development resistance issues and in some cases, generic competition. Antifungals Antibacterials Antivirals As part of its comprehensive coverage, each report includes: Epidemiology including Incidence Statistics for each type of infection. Current Market Size and Revenue Forecasts for each market segment to assist with long term planning. Discussion of Competitive Products in the market and new products in the delivery pipeline. Coverage of Generic...Published: June 1, 2007 | Price: $500.00 – $5,990.00
Multiple sclerosis (MS) is a chronic demyelinating CNS disease that causes significant disability in young adults and others. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life. Kalorama Information's: Multiple Sclerosis Treatments: World Market Outlook to 2011 is one of the few publications to take a detailed look at multiple sclerosis treatment market worldwide, as well as treatments that...Published: October 1, 2007 | Price: $995.00 – $1,990.00
It can be said that pharmaceutical companies face a 'new era.' in the coming years. Old strategies will not produce the same results. A wave of generic competition is poised to affect most brands. Drug companies have had to cut research budgets, leading to a dearth of new products on the market. This means there is very little margin for error in the pricing decision. Drug pricing is one of the key levers that determine the profitability of a drug...Published: October 1, 2007 | Price: $995.00 – $5,000.00
In five years, Kalorama Information believes that given the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off an approved list, and many states allow prescription choice from a physicians diagnosis. The cost of copays and the time spent on doctor visits will...Published: December 1, 2007 | Price: $995.00 – $7,990.00
Kalorama's 2nd edition of The World Cardiovascular Drugs Market, in its 2nd edition, will steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. Analyst Mary Ann Crandall considers both the exisiting products and the pipeline in this comprehensive market study. The following market segments are covered: Cardiac Glycosides and Positive Inotropic Agents Antihypertensive Agents (ACE Inhibitors, Angiotensin...Published: January 1, 2008 | Price: $995.00 – $7,000.00
Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide. Kalorama's Worldwide Market for Rheumatoid Arthritis and Lupus Treatments (Autoimmune Disease Markets) is the most comprehensive look at the markets for...Published: January 1, 2008 | Price: $995.00 – $7,990.00
Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. Pediatric Drugs, the...Published: January 1, 2008 | Price: $4,200.00 – $7,800.00
One of Kalorama's best-selling market research reports, this report provides the reader with a complete analysis of the domestic and international markets for pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatological Drugs is the sixth time Kalorama Information has comprehensively studied the dermatology markets. Kalorama has completely re-evaluated the market from the ground up, and in addition to the usual primary research (interviews) of industry participants, clinicians, and regulators, we also conducted scores...Published: February 1, 2008 | Price: $895.00 – $6,990.00
Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare system pays out more for the care of congestive heart failure than it does for all forms of cancer combined. While this is a challenge for the US healthcare system, it indicates a strong market opportunity for pharmaceutical companies involved in CHF treatment. Kalorama Information's Congestive Heart Failure, Major...Published: March 15, 2008 | Price: $6,995.00 – $13,990.00
Pharmaceutical marketers will face a challenging time in 2008 by all reports. Understanding the dynamics of the market can assist in better planning and strategy. This Kalorama Information Report Bundle combines 5 of the most important topics for those in the pharmaceutical industry in a strategic planning, business development or marketing. Grouped together, this report reprsents over 60% off the individual report price. Retail Clinics These entities may change how America gets healthcare, and may become important outlets for pharmaceutical...Published: April 1, 2008 | Price: $995.00 – $7,990.00
Generics, so long the force that has shaken up the branded pharmaceutical industry, is now facing its own challenges as an industry. While growth indications are strong, there are challenges for generic companies. In the next two years, consolidation will most likely rise; the sector is expected to be rocked by increased competition from companies in Eastern Europe, India and China, as well as brand name companies seeking to protect their franchises by moving into generics. Kalorama Information's World Market...Published: April 1, 2008 | Price: $500.00 – $3,990.00
Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life. Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the US market for prescription drugs likely to switch in the...Published: July 1, 2008 | Price: $500.00 – $7,000.00
Pharmaceutical markets in Brazil, Russia, India and China rank among the top twenty markets in the world with the potential to move up in ranking rather quickly. (China’s pharmaceutical market, for instance, is expected to show double-digit growth over the next five years.) Developing regions and petro-rich nations will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. Kalorama's Pharmaceutical Markets in Brazil, Russia, India and China (BRIC nations) takes a...Published: January 1, 2009 | Price: $995.00 – $7,000.00
This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing of prescription drugs and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. A major factor driving the upward trend in the number of manufacturing projects being outsourced is that specialized production, i.e., sterile manufacturing, biopharmaceutical manufacturing and specialized processes, such as chiral chemistry and improvements in catalyst activity, is often not included in the...Published: February 1, 2009 | Price: $995.00 – $5,990.00
Women’s health encompasses all different areas of medicine and it would be a monumental task to address all of the areas that affect women. This report will concentrate on disorders that affect the female reproductive system and other disorders where there is at least a 70% preponderance of women affected by the disorder. The worldwide prescription drug market for women’s health consists of total manufacturers’ revenues from the following product categories: Autoimmune diseases Cancer Gynecological and Sexually Transmitted Diseases Hormones...Published: May 1, 2009 | Price: $995.00 – $7,000.00
While many areas of the pharmaceutical industry will suffer from current economic conditions worldwide, sales of over the counter drugs are widely anticipated to grow as consumers seek cheaper alternatives. Manufacturers are expected to switch prescription drugs to over the counter status where possible. In the early part of this decade there was a delcine in Rx to switches, since 2006 there has been a number of uses of this tactic to extend revenue of pharmaceutical products. In Kalorama Information's...Published: October 1, 2009 | Price: $3,500.00 – $7,000.00
The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to them. This Kalorama Information The World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance and generic competition. The report focuses on three key segments of...